MDT Stock Trades Cheaper Than Peers Ahead of Q1 Earnings: Time to Buy?

Medtronic (MDT) is scheduled to report Q1 FY26 results on August 19th, with consensus revenue estimated at $8.37 billion (+5.7% YoY) and flat EPS of $1.23, despite a 6.8% decline in recent EPS estimates. While the company has a history of beating earnings, it faces significant headwinds from rising costs, tariffs, unfavorable foreign exchange, and the separation of its Diabetes business. However, MDT has demonstrated underlying business resilience with consistent organic revenue growth driven by new product launches and strategic operational improvements, outperforming its industry and the S&P 500 in Q1. Despite trading at a discount to peers, the outlook remains cautious due to persistent macroeconomic pressures, suggesting investors monitor results for a clearer entry point.

Analysis

Medtronic faces a dichotomic outlook ahead of its fiscal Q1 2026 earnings report, with consensus estimates pointing to solid top-line growth but stagnant profitability. While revenues are projected to increase 5.7% year-over-year to $8.37 billion, earnings per share are expected to be flat at $1.23, reflecting a significant 6.8% downward revision over the past 90 days. This pressure on the bottom line stems from a confluence of headwinds, including elevated raw material and labor costs, an unfavorable foreign exchange impact estimated at 1-2% of revenue, and the full-quarter revenue loss from the separated Diabetes business. These factors contributed to a 70 basis point contraction in adjusted gross margin in the prior quarter. Despite these challenges, the company's underlying fundamentals show resilience, evidenced by consistent mid-single-digit organic growth and a strong product pipeline in high-growth areas like pulse field ablation, TAVR, and robotics. The stock's recent performance, a 9.3% gain in the fiscal first quarter, has outpaced both the S&P 500 and key peers like Abbott and Boston Scientific. This outperformance contrasts with its valuation, as MDT trades at a forward P/E of 16.23X, a notable discount to the industry's 22.00X and its peers, suggesting the market is pricing in the margin compression risks.

Key Decisions for Investors

• Investors should scrutinize the upcoming earnings for any signs of margin stabilization, as the central question is whether strong organic revenue growth can successfully offset the well-documented cost, currency, and portfolio-change headwinds.
• Given the stock's discounted forward P/E of 16.23X relative to peers, a key consideration is whether management's forward guidance provides a credible path to restoring earnings power, which could signal a potential value opportunity.
• Considering the downward EPS estimate revisions and a neutral quantitative earnings prediction model, it may be prudent to await the results and subsequent management commentary for a clearer entry point, particularly to gauge the impact of macroeconomic pressures on future profitability.